Abstract 2631
Background
Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establish their economic value. The objective was to describe OS and costs in French R/M SCCHN patients.
Methods
The EGB, a random representative sample (1/97th) of the French national healthcare system claims database was used. All adult patients with a diagnosis of SCCHN with a first R/M between Jan 2009 and Dec 2014 were selected. Data were analyzed from the index date (first chemotherapy) until patients’ death or Dec 2015 (minimum follow-up of 12 months). Two periods were distinguished: ‘chemotherapy treatment’ (CT) and ‘end-of-life’ (EoL) (from last CT to death). OS was estimated using the Kaplan-Meier method. Costs included all hospitalizations for SCCHN, consultations, medical devices, biology and imaging procedures, supportive and palliative care, transportation, patients’ out of pocket expenses and indirect cost (daily allowances for sick leaves and disability pensions).
Results
Among 267 patients identified, 85% were men, 44% had metastases at the index date and mean age was 62.0 years (±9.9). Most common tumor locations were oropharynx (29%), oral cavity (12%), larynx (10%) and hypopharynx (10%) but 39% of the patient had multiple locations. Median OS was 9.3 months in overall population with no significant difference between recurrent or metastatic patients (10.5 vs. 8.3 months, p = 0.092). The median OS ranged from 8.3 months for tumors located in the oro/hypopharynx to 10.9 months for those in the oral cavity. The average cost per patient was €48,069 breakdown into €31,136 [95CI: 27,935–34,336] for hospitalizations and €16,933 [14,866–19,000] for outpatient care. During CT period (209 days on average), main cost drivers were CT acquisition and administration (€13,755), home care (€2454), transportation (€1954) and physician fees (€1214). During EoL period (125 days), palliative care (€3548), home care (€977), nursing care (€711) and physician fees (€618) were the main cost drivers.
Conclusions
This analysis of real-world data confirms the poor prognosis in patients with R/M SCCHN and provides cost data for future economic evaluations.
Clinical trial identification
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Editorial Acknowledgement
Disclosure
A. Lafuma, C. Le Tourneau, C. Emery, E. Torreton, J. Bonastre: Consultancy: BMS. F-E. Cotté, A-F. Gaudin: Employee: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract